Stage IE nonHodgkin's lymphoma of the testis: a need for a brief aggressive chemotherapy

J Urol. 1989 Mar;141(3):554-6. doi: 10.1016/s0022-5347(17)40891-3.

Abstract

Primary nonHodgkin's lymphoma of the testis is a localized disease in 50 per cent of the cases. Clinical records and pathological material from 9 stage IE cancer patients treated at our institutions were reviewed. All but 1 patient had B cell type lymphomas of intermediate (6) or high (3) grade according to the Working Formulation. Mean survival was 49 months and actuarial survival was 74 per cent at 5 years. Chemotherapy differed with time and frequently was associated with subdiaphragmatic involved field and prophylactic contralateral testis radiotherapy. In view of the good prognosis of patients receiving doxorubicin-based chemotherapy and recent reports on low stage nonHodgkin's lymphoma we recommend an aggressive brief therapy for stage IE lymphoma of the testis after orchiectomy.

MeSH terms

  • Actuarial Analysis
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cobalt Radioisotopes / therapeutic use
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / mortality
  • Male
  • Middle Aged
  • Orchiectomy
  • Radioisotope Teletherapy
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / mortality

Substances

  • Cobalt Radioisotopes
  • Doxorubicin